Clinical trials: Patient With Schizophrenia Spectrum Disorder
Schizophrenia
Efficacy of Bifeprunox in Patients With Schizophrenia
The primary purpose of the study is to evaluate the efficacy of bifeprunox in the maintenance phase of schizophrenia compared to placebo.
- Trial name
- NCT00704509
- Testing
- Bifeprunox, Quetiapine
- Where
- 45 sites in India, Indonesia and 5 more
- Volunteers
- 346 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
Paired Associative Stimulation in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia
The purpose of this study is to 1. assess the effect of PAS in schizophrenia in the dorsolateral prefrontal cortex (DLPFC) 2. assess the effect of PAS induced long-term potentiation (LTP) on the performance of patients with…
- Trial name
- NCT01545999
- Testing
- Brain Stimulation via Transcranial Magnetic Stimulation
- Where
- Canada
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Normal Physiology
Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers
The purpose of this study is to use brain imaging technology to compare differences in brain structure, chemistry, and functioning in individuals with brain and mental disorders compared to healthy volunteers.
- Trial name
- NCT00004571
- Where
- United States
- Volunteers
- 3,273 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.
- Trial name
- ARRIVE US (NCT01432444)
- Testing
- Aripiprazole (Abilify®) IM Depot Injection
- Where
- 124 sites in United States, Canada
- Volunteers
- 493 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
The Management of Schizophrenia in Clinical Practice (MOSAIC)
This study is a disease-based registry designed to follow patients with a DSM-IV-TR (Diagnostic and Statistic Manual of Mental Disorders, Text Revision) diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform…
- Trial name
- NCT01746134
- Where
- 44 sites in United States
- Volunteers
- 557 people
- Sponsor
- Genentech, Inc.
Schizophrenia
A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment
This clinical study will compare the equivalence of two products containing Paliperidone 100 mg in the form of a prolonged release suspension for injection in patients affected by schizophrenia who are already receiving this…
- Trial name
- NCT03425552
- Testing
- Paliperidone
- Where
- 3 sites in Jordan
- Volunteers
- 70 people
- Sponsor
- Pharmathen S.A.
Bipolar Disorder, Mood Disorders
A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of flexible-doses paliperidone ER (3 to 12 mg as needed) compared with placebo over 3 weeks in patients with Bipolar I Disorder who are experiencing an acute…
- Trial name
- NCT00309699
- Testing
- Quetiapine, Paliperidone ER
- Where
- 47 sites in United States, Greece and 6 more
- Volunteers
- 493 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Metabolic Syndrome
Comparison of Berberine and Metformin for the Treatment for MS in Schizophrenia Patients
Berberine is an isoquinoline alkaloid extracted from medicinal herbs, has been demonstrated to produce beneficial effects on diabetes and hyperlipidemia, fewer study reported its modification on lipid metabolism in schizophrenia.
- Conditions
- Schizophrenia, Metabolic Syndrome, Berberine, Metformin
- Trial name
- NCT03708549
- Testing
- Berberine, Metformin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Tianjin Anding Hospital
Schizophrenia
VLT-015 in Patients With Schizophrenia
15 stable patients diagnosed with schizophrenia take 100 mg of VLT-015 once a day, 200 mg of VLT-015 once a day and 200 mg of VLT-015 on two consecutive days with an interval of 24 hours between doses.
- Trial name
- VLT-015 (NCT05516121)
- Testing
- VLT-015
- Where
- 2 sites in Russia
- Volunteers
- 15 people
- Sponsor
- CF Pharma, LLC
Schizophrenia
Add-On Therapy to Risperidonein Schizophrenia
These results suggest that the DA neuroprotection provided by DM in the inflammation-related neurodegenerative models is not mediated through the NMDA receptor.
- Trial name
- DM (NCT01189006)
- Testing
- Dextromethorphan
- Where
- Taiwan
- Volunteers
- 161 people
- Sponsor
- National Cheng-Kung University Hospital
Metabolic Syndrome, Schizophrenia
Topiramate vs Metformin on Cardio-Metabolic Profile in Schizophrenia on Atypical Antipsychotics
Metabolic syndrome is common in patients of schizophrenia. It can add to morbidity, loss of functionality and discontinuation of antipsychotic medication.
- Trial name
- NCT05663749
- Testing
- Metformin, Topiramate
- Where
- India
- Volunteers
- 60 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Schizophrenia, Schizotypal Disorder
Feasibility of a Novel Process-based Treatment for Patients With Psychosis
The purpose of this single-arm feasibility study is to develop and pilot test a novel process-based and modular group therapy approach for patients with acute psychotic symptoms in an inpatient setting.
- Conditions
- Schizophrenia, Schizotypal Disorder, Delusional Disorder, Brief Psychotic Disorder
- Trial name
- PROBAS (NCT04874974)
- Testing
- Metacognitive and Defusion Training
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- Max-Planck-Institute of Psychiatry
Schizophrenia, Schizoaffective Disorder
Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome
The purpose of this study was to determine whether patients with schizophrenia, schizoaffective disorder, or bipolar I disorder who also have metabolic syndrome have a larger decrease in fasting non-high density lipoprotein…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder, Metabolic Syndrome
- Trial name
- NCT00857818
- Testing
- Aripiprazole, Oanzapine, risperidone, or quetiapine
- Where
- 14 sites in Canada
- Volunteers
- 64 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Modafinil Augmentation Therapy for Excessive Daytime Sleepiness and Negative Symptoms in Patients With Schizophrenia
The purpose of this study is to test the effect of modafinil on the negative symptoms, such as blunted affect and social withdrawal, of schizophrenic patients and to determine modafinil's effect on excessive daytime sleepiness.
- Trial name
- NCT00546403
- Testing
- Modafinil
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Veterans Medical Research Foundation
Treatment Resistant Schizophrenia, Clozapine Adverse Reaction
Effect of Atenolol Versus Ivabradine on HRV in TRS Patients on Clozapine With Tachycardia: A Randomised Control Trial.
Clozapine is the only drug approved for Treatment Resistant Schizophrenia. However, it has been associated with many adverse drug reactions including agranulocytosis, myocarditis, sialorrhea, constipation, orthostasis…
- Conditions
- Treatment Resistant Schizophrenia, Clozapine Adverse Reaction, Heart Rate Variability, Tachycardia
- Trial name
- NCT06505668
- Testing
- Atenolol 25 mg, Ivabradine 10mg
- Where
- India
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Psychotic Disorders, Schizoaffective Disorder
Functional Rehabilitation of Older Patients With Schizophrenia
The primary purpose of this project is to evaluate the efficacy of a group therapy intervention, cognitive behavioral social skills training (CBSST), that teaches social functioning skills and cognitive-behavioral compensatory…
- Conditions
- Psychotic Disorders, Schizoaffective Disorder, Schizophrenia
- Trial name
- NCT00237796
- Testing
- Cognitive Behavioral Social Skills Training (CBSST), Goal Focused Supportive Contact (GFSC)
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia, Schizoaffective Disorder
Early Prediction of Clinical Response in Patients With Schizophrenia Treated by Paliperidone ER
Paliperidone ER is a new psychotropic medication for schizophrenia treatment. The studies of 6-week acute treatment and 52-week maintenance treatment showed positive results in patients with schizophrenia and its clinical…
- Trial name
- NCT02075528
- Testing
- Paliperidone ER
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- Taipei City Hospital
Schizophrenia
Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.
This study is designed to evaluate efficacy and safety of HP-3070 compared with placebo transdermal patch in subjects diagnosed with schizophrenia.
- Trial name
- HP-3070 (NCT02876900)
- Testing
- Low Dose Asenapine maleate transdermal patch, High Dose Asenapine maleate transdermal patch
- Where
- United States
- Volunteers
- 617 people
- Sponsor
- Noven Pharmaceuticals, Inc.
Schizophrenia
Control of Metabolic and Cardiovascular Risk in Patients With Schizophrenia and Overweight
To analyse the progress of modifiable metabolic risk factors (Blood pressure, cigarette smoking, waist perimeter, BMI, glycemia and lipidic profile) in schizophrenic patients with overweight for 12 months.
- Trial name
- CRESSOB (NCT00584519)
- Testing
- non-interventional
- Volunteers
- 430 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Hyperprolactinemia
Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine
Antipsychotic drugs can cause a clinically relevant hyperprolactinemia due to blocking the dopamine receptors in the pituitary.Schizophrenic patients suffering from a neuroleptic-induced hyperprolactinemia will be examined…
- Trial name
- NCT00315081
- Testing
- Bromocriptin
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital, Bonn
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.